Dr. Joshua Brody is the Director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai. The Brody lab studies basic and applied tumor immunology for the development of cancer immunotherapies, particularly for lymphomas and melanomas. He talks about dendritic cells to improve oncolytic virus immunotherapy and in situ vaccination to improve PD-1 blockade responses.